Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 772 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metformin Clear all
Terminated Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

NCT02131272
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin detemir, Insulin NPH, Diet/exercise
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Phase 1 Interventional

Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin

NCT01933256
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
HIP2B, Placebo
Drug
Lead sponsor
CureDM
Industry
Eligibility
30 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2016 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Phase 1 Interventional

Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine

NCT01546597
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Jul 22, 2026, 9:16 AM EDT
Withdrawn Phase 1 Interventional

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

NCT05828303
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
TPX-0005, Metformin Hydrochloride, Digoxin, Rosuvastatin Calcium
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Phase 3 Interventional

Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus

NCT00519142
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
placebo for mitiglinide, mitiglinide
Drug
Lead sponsor
Elixir Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
57
States / cities
Glendale, Arizona • Greenbrae, California • La Jolla, California + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2009 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

NCT02077803
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg, CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Phase 4 Interventional

An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.

NCT00391261
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Autism Spectrum Disorders
Interventions
Metformin
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
10 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)

NCT00899470
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed, Saxagliptin/Metformin, Fed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
19 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions

NCT00865241
View directory record Official record
Conditions
Healthy
Interventions
Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Early Phase 1 Interventional

Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer

NCT01911247
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Metformin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Not applicable Interventional

Study of the Effectiveness and Safety of SugarDown vs. Placebo in Type 2 Diabetic Subjects Treated With Metformin

NCT02135549
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
SugarDown, Placebo Oral Tablet
Dietary Supplement · Drug
Lead sponsor
Boston Therapeutics
Industry
Eligibility
25 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Garden City, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

NCT00909597
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
pioglitazone, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
57
States / cities
Buena Park, California • Chino, California • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 22, 2026, 9:16 AM EDT
Terminated Phase 2Phase 3 Interventional

Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients

NCT00622089
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
DIO-902
Drug
Lead sponsor
DiObex
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
12
States / cities
Muscle Shoals, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2008 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Early Phase 1 Interventional

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

NCT01980823
View directory record Official record
Conditions
Breast Cancer, Breast Tumors, Cancer of Breast
Interventions
Metformin, Atorvastatin, Breast surgery
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

NCT06813924
View directory record Official record
Conditions
Healthy Volunteers Sickle Cell Disease, Thalassemia
Interventions
Etavopivat, Digoxin, Pitavastatin, Metformin, Midazolam, Rosuvastatin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Phase 4 Interventional

Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy

NCT00358124
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
insulin glargine, rosiglitazone, metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

Pre-Surgical Study: Effect of Metformin on Breast Cancer Proliferation

NCT00930579
View directory record Official record
Conditions
Breast Cancer
Interventions
Metformin
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Phase 2 Interventional

12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin

NCT00473525
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, PF-00734200 10 mg QD, PF-00734200 20 mg QD, PF-00734200 5 mg QD, PF-00734200 2 mg QD
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
64
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2010 · Synced Jul 22, 2026, 9:16 AM EDT
Withdrawn Phase 3 Interventional

Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes

NCT00754689
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rimonabant, Metformin, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Phase 3 Interventional

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

NCT00039013
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
AC2993, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
129
States / cities
Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Jul 22, 2026, 9:16 AM EDT
Terminated Phase 2 Interventional

Study of RO6807952 in Patients With Diabetes Mellitus Type 2

NCT01516476
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, RO6807952, liraglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 22, 2026, 9:16 AM EDT
Terminated Phase 1 Interventional Results available

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

NCT01525225
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin immediate release (IR), Saxagliptin, Metformin IR, Saxagliptin/Metformin XR FDC, Metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Little Rock, Arkansas • Los Angeles, California • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin

NCT01376323
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK256073 1mg, GSK256073 5mg, GSK256073 10mg, GSK256073 25mg, Placebo, Sitagliptin 100mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Anniston, Alabama • Miami, Florida • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Jul 22, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

NCT02926950
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Placebo, Metformin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Canoga Park, California + 50 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Jul 22, 2026, 9:16 AM EDT